874638-98-9

Basic information

• Product Name: Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- (9CI)
• Synonyms: Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- (9CI);N-(1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide
• CAS NO: 874638-98-9
• Molecular Formula: C₁₇H₁₈FN₃O₅
• Molecular Weight: 363.3403232
• Mol File: 874638-98-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- (9CI)(874638-98-9)
• EPA Substance Registry System: Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)- (9CI)(874638-98-9)

Safety Data

• Hazardous Substances Data: 874638-98-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)(9CI) is used as an anti-cancer agent for its ability to inhibit the growth of cancer cells. It functions by interfering with the DNA replication and repair mechanisms of these cells, thereby limiting their proliferation and spread.
Additionally, it may be utilized in Antiviral Therapy:
Due to its capacity to inhibit viral replication, Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-Methyl-, (2'R)(9CI) may also find applications in antiviral therapy, serving as a potential treatment for viral infections by disrupting the life cycle of the virus.

Upstream product

• 1583260-50-7 (3R,4R,5R)-5-(benzyloxymethyl)-4-(tert-butyldimethylsilyloxy)-3-fluoro-3-methyldihydrofuran-2(3H)-one 
• 26661-13-2 4-N-benzoylcytosine 
• 1583260-54-1 N-(1-((2R,3R,4R,5R)-5-(benzyloxymethyl)-4-(tert-butyldimethylsilyloxy)-3-fluoro-3-methyltetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide 
• 238096-55-4 N-(2-((1-trimethylsilyl)oxy)pyrimidin-4-yl)benzamide 
• 1418141-27-1 C₂₃H₃₂FN₃O₅Si 
• 1583260-48-3 (2R,3R,4R)-isopropyl 5-(benzyloxy)-2-fluoro-3-hydroxy-2-methyl-4-(2,2,6,6-tetramethylpiperidin-1-yloxy)pentanoate 
• 1583260-49-4 (3R,4R,5R)-5-(benzyloxymethyl)-3-fluoro-4-hydroxy-3-methyldihydrofuran-2(3H)-one 
• 817204-34-5 N⁴-benzoyl-1-[2-C-methyl-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl]cytosine 
• 863329-62-8 N⁴-benzoyl-1-(2-C-methyl-3,5-di-O-benzoyl-β-D-arabinofuranosyl)cytosine 
• 65-46-3 CYTIDINE 
• 93-97-0 benzoic acid anhydride 
• 119411-03-9 N-[2-Oxo-1-((2R,3aR,9aR)-5,5,7,7-tetraisopropyl-3-oxo-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-1,2-dihydro-pyrimidin-4-yl]-benzamide 
• 817204-32-3 (2R,3R,4R,5R)-5-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate 
• 817204-33-4 (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidine 

Downstream Products

• 817204-33-4 (2'R)-2'-deoxy-2'-fluoro-2'-methylcytidine 
• 1190307-88-0 sofosbuvir 
• 1064684-44-1 sofosbuvir 
• 863329-66-2 2'-deoxy-2'-fluoro-2'-methyluridine 

Relevant articles and documents

Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation

Resistant HCV variants carrying NS5B S282T mutation confer reduced sensitivity to sofosbuvir, the sole marketed NS5B polymerase inhibitor. On the basis of the finding that 2′-α-F-2′-β-C-methylcytidine 5′-triphosphate (8) was more potent than sofosbuvir's

PROCESS FOR THE PREPARATION OF SOFOSBUVIR

A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein.

Method for preparing (2'R)-2'-deoxy-2-fluoro-2-methyluridine

The invention provides a method for preparing sofosbuvir intermediate (2'R)-2'-deoxy-2-fluoro-2-methyluridine (compound VII), which comprises the following steps: (1) enabling a compound I to react with lithium diisopropylamide in aprotic solvent serving as a reaction solvent, controlling the reaction temperature to 0-5 DEG C, and treating after the reaction is completed to obtain a compound X; and (2) enabling the compound X to react with an NaClO solution having a concentration of 6-10 percent in the existence of a phase transfer catalyst, keeping the reaction temperature to 20-30 DEG C, and treating after the reaction is completed, wherein the reaction solvent is the aprotic solvent. The method does not require column chromatography in post-treatment, has a yield reaching 8 percent, and is applicable to industrial production.

High-yield synthesis method of sofosbuvir and sofosbuvir prepared with method

The invention relates to a high-yield synthesis method of sofosbuvir and sofosbuvir prepared with the method. The method comprises steps as follows: (a) cytidine and benzoic anhydride are dissolved in a first organic solvent for a reaction; TIDPSCl2 is ad

IMPROVED PROCESSES FOR THE PREPARATION OF SOFOSBUVIR AND INTERMEDIATES THEREOF

The present disclosure provides new procedures and intermediates for the preparation of Sofosbuvir.

A general and enantioselective approach to pentoses: A rapid synthesis of PSI-6130, the nucleoside core of sofosbuvir

An efficient route towards biologically relevant pentose derivatives is described. The de novo synthetic strategy features an enantioselective α-oxidation reaction enabled by a chiral amine in conjunction with copper(II) catalysis. A subsequent Mukaiyama aldol coupling allows for the incorporation of a wide array of modular two-carbon fragments. Lactone intermediates accessed via this route provide a useful platform for elaboration, as demonstrated by the preparation of a variety of C-nucleosides and fluorinated pentoses. Finally, this work has facilitated expedient syntheses of pharmaceutically active compounds currently in clinical use.